ACE and hydrops fetalis: We found that T117S carriers had significantly reduced event-free survival (P = 0.02) over a 1.5-year period when compared with noncarriers, despite being given the same standard HF therapy (beta blockers, ACE inhibitors, and aldosterone antagonists) (Figure 8I).